Core Insights - BioArctic reported a transformative year with record financial results, including an operating profit exceeding SEK 1.2 billion and a doubling of cash position [1][2] - The company proposed a dividend of SEK 2.00 per share for the financial year 2025, reflecting its strong financial position [2] Financial Summary - Cash and cash equivalents and short-term investments at the end of the period amounted to SEK 2,190.4 million, up from SEK 778.9 million [1] - Cash flow from operating activities was SEK 313.3 million, compared to a negative SEK 27.4 million in the previous year [1] - Earnings per share before and after dilution were SEK -0.10, improving from SEK -0.36 [1] - Profit for the period was SEK -8.8 million, an improvement from SEK -31.5 million [1] - Operating profit was SEK 33.2 million, compared to SEK -53.5 million in the previous year [1] - Net revenues reached SEK 184.0 million, up from SEK 101.2 million, with SEK 127.0 million in royalties from Leqembi [1] Product Development and Regulatory Updates - Leqembi was approved in over 50 markets, with sales growing each quarter; royalty revenues increased by 31% year-on-year despite currency impacts [1] - The subcutaneous version of Leqembi, Leqembi Iqlik, was launched for maintenance treatment in the US, allowing for home administration [1] - Regulatory reviews for Leqembi Iqlik are ongoing in the US, China, and Japan, with priority reviews granted by the FDA and EMA [1] - The company is working to broaden the availability of Leqembi in Nordic countries and is addressing regulatory challenges in Europe [1] Research and Development Initiatives - BioArctic has strengthened its project portfolio with new initiatives in Huntington's disease and Parkinson's disease, alongside advancing existing projects [1] - Candidate drugs for two projects are being prepared for clinical studies, including one in ALS and another in Parkinson-related disorders [1] - The company is investing in its BrainTransporter technology to enhance the delivery of treatments across the blood-brain barrier [1] - Strong interest in BioArctic's technology and projects has been noted, with opportunities for new strategic partnerships anticipated [1]

Core Insights - BioArctic is expanding its portfolio through new projects and partnerships, particularly highlighting its collaboration with Novartis, which is expected to enhance its treatment offerings for neurodegenerative diseases [3][10]. Financial Performance - For the third quarter of 2025, BioArctic reported net revenues of SEK 133.3 million, a significant increase from SEK 76.6 million in the same period last year. Royalties from Leqembi accounted for SEK 117.2 million, up from SEK 69.8 million [6]. - The company experienced an operating loss of SEK 28.8 million, compared to a loss of SEK 26.1 million in the previous year. The profit for the period was SEK -86.9 million, compared to SEK -19.6 million [6]. - Cash flow from operating activities improved to SEK -41.2 million from SEK -80.3 million, with cash and cash equivalents at SEK 1,882.0 million, up from SEK 804.5 million [6]. Product Development and Market Expansion - Leqembi sales showed a quarter-on-quarter growth of approximately 14%, adjusted for stocking effects in China. The drug is now approved in over 50 countries, with recent approvals in Australia, Canada, and India [4]. - Regulatory approval for monthly intravenous maintenance treatment in China was achieved, marking the fifth market for this dosing regimen. The US also approved weekly subcutaneous maintenance dosing for Leqembi Iqlik [5][6]. - BioArctic's pipeline includes ongoing studies for Exidavnemab and other early projects targeting neurodegenerative diseases, with expectations for results after summer 2026 [11]. Strategic Collaborations - The collaboration with Novartis includes an upfront payment of USD 30 million and aims to combine BioArctic's BrainTransporter technology with Novartis' proprietary antibody for neurodegenerative treatments [6][10]. - The partnership is seen as a significant step in enhancing treatment options for patients and expanding the company's reach in the neurodegenerative disease market [7][10]. Research and Development - New data on lecanemab was presented at the AAIC congress, focusing on long-term efficacy and safety, as well as real-world evidence [6]. - BioArctic is also venturing into Huntington's disease research, aiming to develop disease-modifying treatments, which currently have no available options [12].